Disclosures: David Twitchell: Nothing to Disclose, Dakota Bigham: Nothing to Disclose, Rodolfo Singleterry: Nothing to Disclose, Owais Syed: Nothing to Disclose, Eugenia Tsai: Nothing to Disclose, Fabian Rodas: Nothing to Disclose, Carmen Landaverde: Nothing to Disclose, Jan Petrasek: Nothing to Disclose, Eric Lawitz: Nothing to Disclose, Andres Gomez-Aldana: Nothing to Disclose, Emma Pham: Nothing to Disclose, Amanda Matthews: Nothing to Disclose, Jamiel Ramos: Nothing to Disclose, Kelly Velasquez: Nothing to Disclose, ELIZABETH CALDERA: Nothing to Disclose, Jonathan Inskeep: Nothing to Disclose, Clarissa Vaughn: Nothing to Disclose, Lisa Pedicone: Nothing to Disclose, Fred Poordad: Nothing to Disclose 497 AVOIDING PHLEBOTOMY ENTIRELY: VALIDATION OF A POINT-OF-CARE MEASURE OF APRI & FIB4 FROM FINGER-PRICK BLOOD David Smookler 1 Sarah Tran 2 Bethany Barber 2 Ahreni Saunthar 2 Magdalena Kuczynski 2 Andrew Mendlowitz 2 Aaron Vanderhoff 2 Mia Biondi 2 Camelia Capraru 2 Jordan Feld 3 , 1 Toronto Centre for Liver Disease, 2 VIRCAN/Toronto Centre for Liver Disease, 3 Toronto General Hospital Background: Achieving the World Health Organizations viral hepatitis elimination goals requires decentralized treatment
and third, from empirical combinations to algorithm-guided personalization
Which types of antipsychotics (first or second generation) are more likely to cause an increase in lipid levels
Cardiovascular effects: Transient increases in heart rate and blood pressure possible at higher doses [3]
